EGFR/FLT3/Abl inhibitor SKLB1028

{
  "id": "MLC-T-ONC-013275",
  "term": "EGFR/FLT3/Abl inhibitor SKLB1028",
  "field": "Oncology and biomedicine",
  "definition": "An orally available inhibitor of epidermal growth factor receptor (EGFR), FMS-related tyrosine kinase 3 (FLT3, STK1, CD135 or FLK2), and the non-receptor tyrosine kinase ABL (Abl), with potential antineoplastic activity. Upon administration, the EGFR/FLT3/Abl inhibitor SKLB1028 specifically binds to and inhibits EGFR, FLT3 and Abl, which interferes with the activation of EGFR-, FLT3- and Abl-mediated signal transduction pathways and reduces cell proliferation in cancer cells that overexpress EGFR, FLT3 and/or Abl. EGFR, EGFR and Abl are all overexpressed in a variety of cancers and play key roles in tumor cell proliferation.",
  "synonyms": [
    "multikinase inhibitor SKLB1028"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/egfr-flt3-abl-inhibitor-sklb1028/"
}